AlloVir and Kalaris enter merger to advance retinal disease therapies
The combined entity will operate as Kalaris Therapeutics, with approximately $100m in cash reserves.
deal
Sanofi’s $17bn sale of Opella to US investors advances following government deal
Sanofi signs radioligand therapy licensing deal for rare cancers
UCB to divest China neurology and allergy business for $680m
Rafael Holdings and Cyclo Therapeutics enter merger deal
VION Biosciences acquires Echelon Biosciences
Organon and Lilly expand deal for migraine treatment to new markets
Eli Lilly acquires Morphic in IBD portfolio expansion
